A biopsy of the left vastus laterlis muscle showed foci of fibres with increased numbers of internal nuclei with minimal atrophy. Trichrome staining showed focal groups of fibres with blurring of the myofibrillar network and aggregations of dense staining material (fig 2) . These aggregates were seen by electron microscopy to represent Z-band streaming. NADH staining also showed loss of the myofibrillar network in many fibres, resulting in a targetoid appearance similar to that seen in patient 1. There was no evidence of inflammation, and phosphorylase and myoadenylate staining showed normal activity.
Discussion

$
Ipecac is isolated from the root of Cephalis -ipecacuanha. It contains two major alkaloids, emetine and cephaeline. Cephaeline is primarily responsible for producing nausea and emesis, whereas emetine is more toxic to skeletal muscle and the heart.4 Ipecac has long been used by natives of Brazil to treat diar-/ rhoea and has had widespread use in the treatment of amebiasis. 4 The microscopic pathological changes seen in the muscle biopsies from our patients are very similar to those reported in previous cases of ipecac myopathy' 7 9and experimental emetine-induced myopathy in rats. 8 Light microscopy reveals variation in fibre size, internal nuclei, granular breakdown of myofilaments, and central core changes or targetoid changes in fibres with ATPase or NADH stains. Electron microscopy shows Z-band streaming and dense bodies." Inflammatory infiltrates are not seen.' These findings are characteristic of ipecac myopathy, but are also seen in a variety of other conditions.'2 Although patient 2 was a heavy consumer of alcohol, her muscle biopsy was quite similar to that of patient 1 and demonstrated the characteristic targetoid changes and Z-band streaming of emetine myopathy. The characteristic type II fibre atrophy of chronic alcoholic myopathy'3 was absent and therefore her myopathy was likely predominately due to emetine toxicity. The effects on cardiac muscle are not as well documented, but interstitial oedema, inflammation, and degenerative change of myocardial fibres have been reported. 3 Therapy consists of discontinuing ipecac use and employing supportive measures. If cardiomyopathy is significant, inotropic and afterload reducing agents may be used. As shown in patient 1, both the cardiomyopathy and myopathy improved after discontinuing ipecac abuse. Electrical and pathological evidence of muscle recovery has also be demonstrated.9 12 
